Skip to main content
Clinical Trials/NCT04317846
NCT04317846
Completed
Not Applicable

TransRadIal Evaluation STudy of diamEter Increase After Vasodilatory Drugs Administration: The TRIESTE Randomized Study

University of Lausanne Hospitals2 sites in 1 country165 target enrollmentMarch 22, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Arterial Spasm
Sponsor
University of Lausanne Hospitals
Enrollment
165
Locations
2
Primary Endpoint
Maximal radial artery diameter dilation, measured by echo-doppler, after administration of vasodilatory drugs by intravenous or intra-radial route.
Status
Completed
Last Updated
last year

Overview

Brief Summary

Radial artery access use in percutaneous cardiac interventions (PCI) is associated with a lower risk of vascular complications, bleeding and major adverse cardiac events including cardiac death in the long-term follow-up. Intra-radial administration of vasodilatory drugs, transiently painful for the patient, reduces the risk of spasm and is currently the standard technique performed worldwide. However, the efficacy of intravenous administration of vasodilatory drugs has never been evaluated.

Detailed Description

Multicenter, randomised controlled trial, designed to evaluate the noninferiority of the intravenous administration of vasodilatory drugs in comparison with the actual gold standard intra-arterial radial route, in terms of radial artery diameter increase. All consecutive patients with stable ischemic disease or stable acute coronary syndrome (NSTEMI - Non-ST elevation myocardial infarction) for whom a coronary procedure is planned will be included in the study. Three groups will be constituted. For all groups, the diameters of both radial arteries will be measured thrice by echo-Doppler: 5 minutes before sheath insertion, immediately before sheath insertion and 5 minutes after sheath insertion. Pain evaluation will be performed after injection of the vasodilatory drugs/placebo in the radial artery: * Group 1 (control group): intra-radial administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg) * Group 2 (intravenous-post): intra-venous administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg) * Group 3 (intravenous-pre): intra-venous administration of the vasodilatory drugs 5 minutes before sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)

Registry
clinicaltrials.gov
Start Date
March 22, 2021
End Date
June 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of Lausanne Hospitals
Responsible Party
Principal Investigator
Principal Investigator

Vladimir Rubimbura

Principal Investigator, Dr Vladimir Rubimbura

University of Lausanne Hospitals

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Maximal radial artery diameter dilation, measured by echo-doppler, after administration of vasodilatory drugs by intravenous or intra-radial route.

Time Frame: 5 minutes after vasodilatory drugs administration

Radial artery diameter

Secondary Outcomes

  • Pain evaluation after vasodilatory drugs administration using the intravenous versus intra-radial route(Procedure (During vasodilatory drugs administration))
  • Hemodynamic changes after vasodilatory drugs administration using the intravenous versus intra-radial route(5 minutes after vasodilatory drugs administration)
  • Heart rate change after vasodilatory drugs administration using the intravenous versus intra-radial route(5 minutes after vasodilatory drugs administration)

Study Sites (2)

Loading locations...

Similar Trials